<DOC>
	<DOCNO>NCT00391989</DOCNO>
	<brief_summary>The primary objective trial estimate activity BMS-354825 ( Dasatinib ) de novo adult Ph+ ALL patient term hematological complete remission ( HCR ) rate .</brief_summary>
	<brief_title>Treatment Adult Ph+ LAL With BMS-354825</brief_title>
	<detailed_description>This open label phase II study Dasatinib enroll adult de novo Ph+ ALL patient . A minimum 48 case require complete study . Accrual expect complete 18 month . The study consider complete patient HCR completion total 12 week treatment . After completion patient go study treat accord best treatment option Ph+ ALL patient 1st HCR . The enrollment post-remissional phase current GIMEMA LAL protocol suggest .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Dasatinib</mesh_term>
	<criteria>Patients Ph+ and/or BCR/ABL+ ALL Age ≥18 year old De novo ALL ( within 14 day diagnosis ) No prior treatment antileukemic drug exception steroid 14 day ( include 7day pretreatment already schedule protocol ) WHO performance status ≤2 Absence central nervous system ( CNS ) leukemia Normal serum level potassium , total calcium correct serum albumin magnesium phosphorus , correctable supplement ALT AST ≤2.5 x ULN ≤5.0 x ULN consider due leukemia Alkaline phosphatase ≤2.5 x ULN unless consider leukemia Serum bilirubin ≤2 x ULN Serum creatinine ≤3 x ULN Serum amylase ≤1.5 x ULN serum lipase ≤1.5 x ULN Normal cardiac function Written inform consent prior study procedure perform . Impaired cardiac function , include one following : Impairment gastrointestinal ( GI ) function GI disease may significantly alter absorption BMS354825 ( e.g. , ulcerative disease , uncontrolled nausea , vomit , diarrhoea , malabsorption syndrome , small bowel resection ) Use therapeutic warfarin Acute chronic liver renal disease consider unrelated leukemia Other concurrent severe and/or uncontrolled medical condition ( e.g. , uncontrolled diabetes , active uncontrolled infection ) could cause unacceptable safety risk compromise compliance protocol Treatment hematopoietic colonystimulating growth factor ( e.g. , GCSF , GM¬CSF ) ≤1 week prior start study drug Patients currently receive treatment medication list `` Appendix F '' treatment either discontinue switched different medication prior start study drug . The medication list `` Appendix F '' potential prolong QT interval . Patients receive antileukemic agent treatment include steroid 14 day include 7 day pretreatment part protocol Patients receive investigational drug last 2 week Patients undergone major surgery ≤2 week prior start study drug recover side effect therapy Patients pregnant breast feeding , adult reproductive potential employ effective method birth control . ( Women childbearing potential must negative serum pregnancy test within 48 hrs prior administration BMS354825 ) . Postmenopausal woman must amenorrheic least 12 month consider nonchildbearing potential . Male female patient must agree employ effective barrier method birth control throughout study 3 month follow discontinuation study drug Known diagnosis human immunodeficiency virus ( HIV ) infection ( HIV test mandatory ) Patients history another primary malignancy currently clinically significant currently require active intervention Non compliant oral medication patient .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Ph+ Acute Lymphoblastic Leukaemia</keyword>
	<keyword>Dasatinib</keyword>
	<keyword>target therapy</keyword>
	<keyword>Patients Ph positive BCR ABL positive ALL</keyword>
</DOC>